How GLP‑1 receptor agonists affect unhealthy organ fat in people with chronic kidney disease
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease
This observational project will test whether taking GLP‑1 receptor agonist medicines changes harmful fat around organs and related inflammation in adults with chronic kidney disease who also have obesity or type 2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Cardenal Herrera University Academic / other |
| Locations | 1 site (Valencia, Valencia) |
| Trial ID | NCT07309094 on ClinicalTrials.gov |
What this trial studies
This is an observational cohort study that follows adults with CKD stages G1–G4, comparing those treated with GLP‑1 receptor agonists to those not receiving these drugs while recording other glucose‑lowering therapies. Investigators will use imaging (CT/MRI), bioimpedance, morphometric measures, and blood biomarkers to quantify perivisceral adipose tissue, radiodensity, and pro‑inflammatory adipokines alongside kidney function measures. The study documents real‑world use of GLP‑1RAs, SGLT2 inhibitors, tirzepatide and other medications rather than assigning treatments. Data will be analyzed to link changes in adipose tissue characteristics with biochemical markers and clinical measures of kidney and cardiovascular risk.
Who should consider this trial
Good fit: Adults aged 18 or older with chronic kidney disease stages G1–G4 (not on dialysis) who have uncontrolled type 2 diabetes, obesity, and/or cardiovascular disease and who can give informed consent are appropriate candidates.
Not a fit: People with end‑stage CKD (stage G5) or candidates for dialysis, pregnant individuals, or those with neuropsychiatric conditions preventing informed consent are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could show that GLP‑1RAs reduce harmful periorgan fat and inflammation, which might help slow CKD progression and lower cardiovascular risk.
How similar studies have performed: Previous randomized and observational studies have shown renal and cardiovascular benefits of GLP‑1RAs in people with type 2 diabetes and obesity, but direct, detailed links between GLP‑1RA use and improvements in perivisceral adiposopathy remain less well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> or = 18 years of age * diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis * had uncontrolled T2DM, CVDs and/or obesity * willing to participate in the study and sign informed consent Exclusion Criteria: * Age \<18 years * pregnancy * CKD in stage G5 or G4 candidate for dialysis * neuropsychiatric diseases preventing the patient from understanding the benefits/risks associated with the project * refusal to participate and/or consent revocation were considered as exclusion criteria
Where this trial is running
Valencia, Valencia
- Vithas Valencia Consuelo — Valencia, Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Luis D'Marco, MD, PhD — Cardenal Herrera University
- Study coordinator: Ana Checa-Ros, MD, PhD
- Email: ana.checaros@uchceu.es
- Phone: +34 961369000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.